tbuckley/cabot-search huggingface dataset:
Comparison of carnivore, omnivore, and herbivore mammalian genomes with a new leopard assembly
Authors: Soonok Kim, Yun Sung Cho, Hak-Min Kim, Oksung Chung, Hyunho Kim, Sungwoong Jho, Hong Seomun, Jeongho Kim, Woo Young Bang, Changmu Kim, Junghwa An, Chang Hwan Bae, Youngjune Bhak, Sungwon Jeon, Hyejun Yoon, Yumi Kim, JeHoon Jun, HyeJin Lee, Suan Cho, Olga Uphyrkina, Aleksey Kostyria, John Goodrich, Dale Miquelle, Melody Roelke, John Lewis, Andrey Yurchenko, Anton Bankevich, Juok Cho, Semin Lee, Jeremy S. Edwards, Jessica A. Weber, Jo Cook, Sangsoo Kim, Hang Lee, Andrea Manica, Ilbeum Lee, Stephen J. O’Brien, Jong Bhak, Joo-Hong Yeo
Journal: Genome biology (2016)

There are three main dietary groups in mammals: carnivores, omnivores, and herbivores. Currently, there is limited comparative genomics insight into the evolution of dietary specializations in mammals. Due to recent advances in sequencing technologies, we were able to perform in-depth whole genome analyses of representatives of these three dietary groups. We investigated the evolution of carnivory by comparing 18 representative genomes from across Mammalia with carnivorous, omnivorous, and herbivorous dietary specializations, focusing on Felidae (domestic cat, tiger, lion, cheetah, and leopard), Hominidae, and Bovidae genomes. We generated a new high-quality leopard genome assembly, as well as two wild Amur leopard whole genomes. In addition to a clear contraction in gene families for starch and sucrose metabolism, the carnivore genomes showed evidence of shared evolutionary adaptations in genes associated with diet, muscle strength, agility, and other traits responsible for successful hunting and meat consumption. Additionally, an analysis of highly conserved regions at the family level revealed molecular signatures of dietary adaptation in each of Felidae, Hominidae, and Bovidae. However, unlike carnivores, omnivores and herbivores showed fewer shared adaptive signatures, indicating that carnivores are under strong selective pressure related to diet. Finally, felids showed recent reductions in genetic diversity associated with decreased population sizes, which may be due to the inflexible nature of their strict diet, highlighting their vulnerability and critical conservation status. Our study provides a large-scale family level comparative genomic analysis to address genomic changes associated with dietary specialization. Our genomic analyses also provide useful resources for diet-related genetic and health research.
TCT-443 Cost and Utilization Among Patients After Incident Percutaneous Coronary Intervention
Authors: Matthew D. Solomon, Thomas K. Leong, Sue Hee Sung, Alda Inveiss, John B. Hernandez, Roseann M. White, Michelle Sosa, Edward J. McNulty, Alan S. Go
Journal: Journal of the American College of Cardiology (2015)
Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC).
Authors: Christopher N. Graham, Hediyyih N. Knox, Katherine B. Winfree, Lisa M. Hess, Jingyi Liu, Waldo Feliu Ortuzar, Ralph Zinner
Journal: Journal of Clinical Oncology (2013)

263 Background: The PRONOUNCE trial was a phase III, randomized, open-label U.S. study comparing pemetrexed (PemC) with bevacizumab (PCB) in the treatment of advanced chemo-naive nonsquamous non-small cell lung cancer (NS-NSCLC). The primary endpoint of improved PFS without grade 4 toxicity for PemC over PCB was not met. There were no differences in PFS or OS. This analysis was conducted to estimate differences in costs of treatment and related patient care between the groups to inform evidence-based treatment decision making. Methods: A cost-minimization analysis was performed using data from the PRONOUNCE trial and publically available U.S. unit costs. Drug costs modeled included induction, maintenance, and subsequent therapies. Other estimated medical costs were drug administration, concomitant medications, and treatment of grade 3/4 toxicities. A probabilistic sensitivity analysis (PSA) was conducted to model joint uncertainty associated with model parameters. Results: The average cost of treatment with PemC was $4,689 less than PCB ($30,334 vs $35,024). Drug acquisition and administration costs were less in all modeled settings (induction, maintenance, and subsequent lines) for PemC. Costs associated with concomitant medications and grade 3/4 toxicities were similar ($13,286 vs $13,738). PemC was cost saving in 99% of 10,000 PSA iterations. Conclusions: Based on the PRONOUNCE trial and model results, PemC may present a similarly effective but less costly treatment option for patients in the United States compared with PCB. While treatment decision making should consider the overall safety profile and patient preferences, this study provides estimates of the costs of treatment of these two therapeutic options. The analysis was based on clinical trial data; therefore, the results may not be generalizable to all patients. [Table: see text]
Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by &gt;10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and <i>DelTP53</i> in TT2
Authors: B. Barlogie, E. J. Anaissie, F. van Rhee, J. D. Shaughnessy, J. Haessler, M. Pineda-Roman, K. Hollmig, J. Epstein, J. J. Crowley
Journal: Journal of Clinical Oncology (2008)

8516 Background: The introduction of transplants in the 1980’s and novel agents in the 1990’s has markedly improved MM survival. TT trials applied all active treatment ingredients up-front with the objective to maximize long-term disease control. As novel agent combinations are increasingly being applied at the exclusion of transplants, it appears useful to establish a historical framework of long-term outcomes with our TT approach introduced in 1989. Methods: An update is provided of overall survival (OS), event-free survival (EFS), CR rates and CR durations for TT1 (n=231; phase II, interferon maintenance), TT2 (n=668; phase III, ± thalidomide, post-transplant consolidation) and TT3 (n=303; phase II, added bortezomib and thalidomide throughout). Results: Stringently defined CR increased significantly from 40% in TT1 to 50% in TT2 to 60% in TT3. Median CR duration increased from 2.5yr in TT1 (16 in CCR beyond 10yr) to 5.0yr in TT2; the 3-yr estimate in TT3 is 90%. Median EFS and OS were 2.6yr and 5.7yr for TT1 and 5.0yr and 9.0yr for TT2; the 3-yr estimates in TT3 are 80% and 85%. A gene array-based high-risk score adversely affected OS, EFS and CR duration in both TT2 and TT3. However, the independent adverse implications, for all 3 endpoints, of t (4;14) and TP53 deletion observed in TT2 did not pertain to TT3, supporting a major role of bortezomib, added in TT3, for the management of these hitherto high-risk MM subsets. Conclusions: A CCR plateau apparent at 10yr in TT1 is consistent with a ∼10% cure rate. Significant improvements beyond TT1 with TT2 and especially TT3 bode well for marked increases in 10-yr OS and cure rates. Knowledge of t(4;14) and delTP53 status is key to identifying MM subsets uniquely benefiting from bortezomib. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Millennium
Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy
Authors: TaeHyung Kim, Marc S. Tyndel, Hyeoung Joon Kim, Jae-Sook Ahn, Seung Hyun Choi, Hee Jeong Park, Yeo-kyeoung Kim, Soo Young Kim, Jeffrey H. Lipton, Zhaolei Zhang, Dennis (Dong Hwan) Kim
Journal: Blood (2016)
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
Authors: Ashley A. Basiorka, Kathy L. McGraw, Erika A. Eksioglu, Xianghong Chen, Joseph Johnson, Ling Zhang, Qing Zhang, Brittany A. Irvine, Thomas Cluzeau, David A. Sallman, Eric Padron, Rami Komrokji, Lubomir Sokol, Rebecca C. Coll, Avril A. B. Robertson, Matthew A. Cooper, John L. Cleveland, Luke A. O’Neill, Sheng Wei, Alan F. List
Journal: Blood (2016)
Seven Year Follow up of Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib 400 Mg Twice Daily - a Single Center Study at MDACC
Authors: Binsah Susan George, Hagop M Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Srdan Verstovsek, Gautam Borthakur, Nitin Jain, Sherry Pierce, Koichi Takahashi, Elias Jabbour, Jorge E. Cortes
Journal: Blood (2015)
GW27-e0656 Zotarolimus eluting Resolute Integrity versus Everolimus eluting Xience Xpedition stents in the management of very long native coronary artery stenosis- A retrospective comparative real world study with propensity match analysis
Authors: Soumya Patra, Rabindranath Chakraborty
Journal: Journal of the American College of Cardiology (2016)
Imatinib Mesylate Reduces Rituximab-Induced Tumor Growth Inhibition In Vivo on EBV-Associated Human B-Cell Lymphoma.
Authors: Fariba Némati, Claire Mathiot, Isabelle Grandjean, Olivier Lantz, Vincent Bordier, Sébastien Dewulf, Richard Ekue, James P. Di Santo, Marie-France Poupon, Didier Decaudin
Journal: Blood (2007)
GW27-e0925 KOSEN-CHA, a functional green tea, improves obesity and vascular function
Authors: Yusuke Tsutsui, Yasufumi Katanasaka, Yoichi Sunagawa, Tatsuhide Inoue, Hideaki Moriwaki, Yasuo Shimizu, Shigeharu Narushima, Toshio Maeda, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto
Journal: Journal of the American College of Cardiology (2016)
Comparison of Thalidomide and Lenalidomide for the Treatment of Patients (pts) with Myelofibrosis (MF).
Authors: Elias Jabbour, Hagop Kantarjian, Sameer A Parikh, Deborah Thomas, Tapan Kadia, Guillermo Garcia Manero, Gautam Borthakur, Sherry Pierce, Mark Brandt, Jorge Cortes, Srdan Verstovsek
Journal: Blood (2009)
GW27-e1152 Activation of cannabinoid receptor II -CB2 ameliorates cardiac fibrosis after myocardial infarction via Nrf2-mediated inhibition of TGFβ-1/Smad3 pathway
Authors: Xiang Li, Dong Han, Yabin Wang, Miaomiao Fan, Xiujuan Li, Feng Cao
Journal: Journal of the American College of Cardiology (2016)
TCT-433 Expansion of Ileofemoral Access to &lt;5 mm with Recollapsible Sheath in High Risk TAVR Patients is Feasible with Zero Complication
Authors: Walid K. Abu Saleh, Gilbert H. Tang, Hasan Ahmad, Martin Cohen, Cenap Undemir, Steven L. Lansman, Nivas Balasubramaniyam, Manuel Reyes, Colin Barker, Neal Kleiman, Michael J. Reardon, Basel Ramlawi
Journal: Journal of the American College of Cardiology (2015)
TCT-582 The frequency of the Stent Fracture per Lesion: the Comparison between First and New Generation Drug-Eluting Stent
Authors: Hiroto Yagasaki, Yusuke Hyodo, Suguru Otsuru, Daiji Hasegawa, Seiji Habara, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto, Kazushige Kadota, Kazuaki Mitsudo
Journal: Journal of the American College of Cardiology (2015)
Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma
Authors: Rachel C. Brennan, Ibrahim Qaddoumi, Shenghua Mao, Jianrong Wu, Catherine A. Billups, Clinton F. Stewart, Mary Ellen Hoehn, Carlos Rodriguez-Galindo, Matthew W. Wilson
Journal: Journal of Clinical Oncology (2016)

Purpose To evaluate topotecan-based therapy for advanced intraocular retinoblastoma. Patients and Methods Twenty-seven patients with bilateral retinoblastoma (male patients, n = 14; median age, 8.4 months) received chemotherapy: two courses of topotecan plus vincristine followed by three alternating administrations of carboplatin and vincristine for two courses and topotecan plus vincristine for one course, with optional periocular carboplatin. Focal therapy was applied after cycle 2. Event-free survival was defined as avoidance of external-beam radiotherapy (EBRT) and enucleation. Results Of 54 eyes, 42 were Reese-Ellsworth group IV to V, and 37 were International Classification of Retinoblastoma group C to E. Eleven eyes were enucleated: one at diagnosis, nine with progressive disease including three eyes treated with EBRT, and one that developed neovascular glaucoma after completion of therapy. One patient was removed from protocol with prolonged infection in course 1; 26 patients (51 eyes) were analyzed. At 10 years, cumulative incidence of EBRT was 5.9% (SE ± 3), and event-free survival was 69.2% (SE ± 27.2). Ocular survival for Reese-Ellsworth group IV to V eyes was 77.5% (SE ± 21.2); it was 74.3% (SE ≥ 18.8) for International Classification group C to E eyes. Vision testing (median age, 7 years; range, 5 to 10 years) documented 20/70 vision or better in one eye of 23 patients; 19 (76%) of 25 patients demonstrated 20/40 vision or better in one eye. All patients experienced thrombocytopenia (41 episodes in 275 courses; 15%). There were 29 episodes of febrile neutropenia (10%). Grade 3 diarrhea was present in nine of 27 patients, and one patient had an allergic reaction to carboplatin. All patients are alive at median follow-up 7.4 years (range, 2.7 to 10 years). Conclusion Topotecan combined with vincristine, carboplatin, and aggressive focal therapies is an effective regimen for the treatment of advanced retinoblastoma and results in globe salvage with vision. Toxicities were anticipated and managed with appropriate supportive care.
TCT-383 Impact of Diabetes on Renoprotective Effect of Remote Ischemic Peri-conditioning Before Hospital Arrival of Patients with ST-segment Elevation Myocardial Infarction
Authors: Oladipupo Olafiranye, Adetola Ladejobi, Christian Martin-Gill, Catalin Toma
Journal: Journal of the American College of Cardiology (2015)
TCT-502 Attenuated Coronary Flow Reserve Early after Implantation of a Bioresorbable Vascular Scaffold: one-month results of the VANISH-trial
Authors: Wynand Stuijfzand, Roel Driessen, Jorrit Lemkes, Alexander Nap, Pieter G. Raijmakers, Adriaan A. Lammertsma, Albert C. van Rossum, Yolande Appelman, Maarten van Leeuwen, Niels van Royen, Paul Knaapen
Journal: Journal of the American College of Cardiology (2015)
Defects in Filamin A (FLNa) in Women with X-Linked Filaminopathies: Abnormalities in Platelet Production and Platelet Function
Authors: Paquita Nurden, Marijke Bryckaert, Eliane Berrou, Frédéric Adam, Jean-Marie Daniel Lamazière, Anne-Cécile Pons, Cyril Goizet, William Vainchenker, Alan T. Nurden, Najet Debili
Journal: Blood (2011)
Three-Drug Induction and BFM-Type Intensive Consolidation Chemotherapy for Treatment of Standard Risk Childhood Acute Lymphoblastic Leukemia Defined Also by DNA index. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Study ALL-9501.
Authors: Maurizio Arico’, Valentino Conter, Maria Grazia Valsecchi, Marie France Pinta Boccalatte, Elena Barisone, Chiara Messina, Giulio De Rossi, Luca Lo Nigro, Andrea Pession, Franco Locatelli, Concetta Micalizzi, Giuseppe Basso, Giuseppe Masera
Journal: Blood (2004)
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
Authors: Lauren Van Der Kraak, Gaurav Goel, Krishnaveni Ramanan, Christof Kaltenmeier, Lin Zhang, Daniel P. Normolle, Gordon J. Freeman, Daolin Tang, Katie S. Nason, Jon M. Davison, James D. Luketich, Rajeev Dhupar, Michael T. Lotze
Journal: Journal for ImmunoTherapy of Cancer (2016)

<h3>Background</h3> Resistance to chemotherapy is a major obstacle in the effective treatment of cancer patients. B7-homolog 1, also known as programmed death ligand-1 (PD-L1), is an immunoregulatory protein that is overexpressed in several human cancers. Interaction of B7-H1 with programmed death 1 (PD-1) prevents T-cell activation and proliferation, sequestering the T-cell receptor from the cell membrane, inducing T-cell apoptosis, thereby leading to cancer immunoresistance. B7-H1 upregulation contributes to chemoresistance in several types of cancer, but little is known with respect to changes associated with 5-fluorouracil (5-FU) or gastrointestinal cancers. <h3>Methods</h3> HCT 116 p53<sup>+/+</sup>, HCT 116 p53<sup>−/−</sup> colorectal cancer (CRC) and OE33 esophageal adenocarcinoma (EAC) cells were treated with increasing doses of 5-FU (0.5 uM, 5 uM, 50 uM, 500 uM) or interferon gamma (IFN-γ, 10&nbsp;ng/mL) in culture for 24&nbsp;h and B7-H1 expression was quantified using flow cytometry and western blot analysis. We also evaluated B7-H1 expression, by immunohistochemistry, in tissue collected prior to and following neoadjuvant therapy in 10 EAC patients. <h3>Results</h3> B7-H1 expression in human HCT 116 p53<sup>+/+</sup> and HCT 116 p53<sup>−/−</sup> CRC cells lines, while low at baseline, can be induced by treatment with 5-FU. OE33 baseline B7-H1 expression exceeded CRC cell maximal expression and could be further increased in a dose dependent manner following 5-FU treatment in the absence of immune cells. We further demonstrate tumor B7-H1 expression in esophageal adenocarcinoma patient-derived pre-treatment biopsies. While B7-H1 expression was not enhanced in post-treatment esophagectomy specimens, this may be due to the limits of immunohistochemical quantification. <h3>Conclusions</h3> B7-H1/PD-L1 expression can be increased following treatment with 5-FU in gastrointestinal cancer cell lines, suggesting alternative mechanisms to classic immune-mediated upregulation. This suggests that combining 5-FU treatment with PD-1/B7-H1 blockade may improve treatment in patients with gastrointestinal adenocarcinoma.
FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R].
Authors: Myron S. Czuczman, John P. Leonard, Jeffrey L Johnson, Sin- Ho Jung, Eric Hsi, John C. Byrd, Bruce D. Cheson
Journal: Blood (2008)
A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption
Authors: T. Suarez, K. Fizazi, Y. Rahim, J. Wilson, M. Fan, S. Jun, A. Lipton
Journal: Journal of Clinical Oncology (2006)

8562 Background: Pts on established (≥ 8 weeks) IV BP who have elevated bone resorption markers, especially urinary N-telopeptide (uNTx), are at increased risk for skeletal related events (Coleman, J Clin Oncol 2005). Denosumab, a fully human monoclonal antibody, inhibits osteoclastic bone resorption by binding and neutralizing RANK ligand, a key mediator of osteoclast differentiation and function. Denosumab efficacy and safety were evaluated in a phase 2, randomized, open label, active-controlled study in advanced cancer pts with BM and elevated levels of uNTX despite established IV BP therapy. We report preliminary results from an interim analysis of 49 pts at week 13. Methods: Eligible pts (≥18 yrs old with solid tumor [except lung] or multiple myeloma [MM]; confirmed BM; screening uNTx &gt; 50 nM BCE/mM creatinine [Cr]; on IV BP for ≥ 8 weeks before randomization) are stratified by baseline uNTx (50–100, &gt;100) and tumor type. Pts are randomized to 1 of 3 arms: IV BP every 4 weeks (Q4W) or 180 mg denosumab given subcutaneously Q4W or Q12W. The primary endpoint is the proportion (%) of pts with uNTx &lt; 50 nM BCE/mM Cr at week 13. Enrollment is ongoing (planned N = 135). Results: The mean (range) age of all pts in the analysis (33 denosumab; 16 BP) was 62.5 (39, 81) yrs; 96% had &gt; 2 BM. The median time on prior IV BP (mostly zoledronic acid) was 5.1 months. Tumors included prostate (n = 24), breast (n = 20), other/MM (n = 5). The % of pts with uNTx &lt; 50 nM BCE/mM Cr at week 13 was greater with denosumab (pooled arms) than IV BP: 76% (95% CI: 60.3, 91.2) vs 38% (95% CI: 18.5, 61.4; P = .015 Cochran-Mantel-Haenzel), respectively. No treatment-related serious adverse events (SAEs) were reported. Commonly reported AEs in the denosumab arms included nausea, peripheral edema, anemia, bone pain, and constipation. At data cutoff, 10 deaths (6/33 denosumab, 4/16 BP) had occurred on-study. Conclusions: These interim data suggest that denosumab normalizes uNTx more frequently than IV BP in pts with elevated uNTx despite 8 weeks of IV BP, across all tumor types. The AE profile of denosumab appeared similar to that of cancer pts undergoing treatment. [Table: see text]
Liberty versus Need — Our Struggle to Care for People with Serious Mental Illness
Authors: Lisa Rosenbaum
Journal: New England Journal of Medicine (2016)

Interview with Dr. Christine Montross on treatment and confinement of people with serious mental illness. (15:34)Download Of 9.8 million U.S. adults with serious mental illness, an estimated 40% receive no treatment in any given year, often with dire consequences. But the structural impediments to care can’t be addressed without reconciling the conflicting ideals underlying them.
GW27-e0534 Atrial denervation induces long-term damage to target atrial tissue in canine models
Authors: Ximin Wang, Xuling Li, Xiaohong Zhang, Ming Zhang, Yujiao Zhang, Zhan Li, Haiyan Wang, Weizong Wang, Zhongsu Wang, Yinglong Hou
Journal: Journal of the American College of Cardiology (2016)
TCT-463 Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting In Left Main Coronary Artery Disease: Long-Term Follow-Up Meta-Analysis Of 6156 Patients
Authors: Aakash Garg, Marco G. Mennuni, Kleanthis Theodoropoulos, Abhishek Sharma, John Kostis, Giulio G. Stefanini
Journal: Journal of the American College of Cardiology (2015)
TCT-516 Bioresorbable Vascular Scaffolds for the Treatment of Small Vessel Disease: Results from a 3-Center Italian Experience
Authors: Bernardo Cortese, Francesco Granata, Alfonso Ielasi, Roberto Adriano Latini, Elisabetta Moscarella, Maurizio Tespili, Pedro Silva Orrego, Attilio Varricchio
Journal: Journal of the American College of Cardiology (2015)
TCT-584 First- Versus Second-Generation Drug-Eluting Stents in Coronary Chronic Total Occlusions: 3-Year Results of a Multicenter Registry: A Propensity-Matched Analysis
Authors: Jong-Hwa Ahn, Jeong Hoon Yang, Kyu Tae Park, Young Bin Song, Joo-Yong Hahn, Jin-Ho Choi, Sang Hoon Lee, Hyeon-Cheol Gwon, Seung-Hyuk Choi
Journal: Journal of the American College of Cardiology (2015)
TCT-230 Culprit Lesion Location and Outcome in Patients with Cardiogenic Shock Complicating Myocardial Infarction: A Substudy of the IABP-SHOCK II-Trial
Authors: Georg Fuernau, Karl Fengler, Steffen Desch, Ingo Eitel, Franz-Josef Neumann, Antoinette de Waha, Suzanne de Waha, Gert Richardt, Klaus Empen, Rainer Hambrecht, Christian Jung, Michael Boehm, Janine Pöss, Gerhard Schuler, Karl Werdan, Uwe Zeymer, Holger Thiele
Journal: Journal of the American College of Cardiology (2015)
Elevated Blood Lead Levels Among Employed Adults — United States, 1994–2013
Authors: Walter A. Alarcon, Sherri Davidson, Brigitte Dufour, Matthew Roach, Kaleb Tsang, Susan F. Payne, Amanda M. DeLoreto, Thomas St. Louis, Sudha Rajagopalan, Sharon Watkins, Juanita Chalmers, Tiefu Shen, Jeffery M. Turner, Kathy Leinenkugel, MaAdwoa Asamoah, Jocelyn Lewis, Ezattolah Keyvan, Kenneth Roseman, Joanna Kica, Stephanie Yendell, Carol R. Braun, Derry Stover, Marija Borjan, Margaret E. Lumia, Devendra Singh, Edward O. Irobi, Heidi Krapfl, Alicia M. Fletcher, Sheila Higgins, Susan J. Quigley, Christin T. Benner, David Dreher, Oregon Health Authority, Tanecia Richardson, Mike Sullivan, Carrie Tomasallo, Steve Melia
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

CDC's National Institute for Occupational Safety and Health (NIOSH) and state health departments collect data on laboratory-reported adult blood lead levels (BLLs). This report presents data on elevated BLLs among employed adults (defined as persons aged ≥16 years) in the United States for 1994-2013. This report is a part of the Summary of Notifiable Noninfectious Conditions and Disease Outbreaks - United States, which encompasses various surveillance years but is being published in 2016 (1). The Summary of Notifiable Noninfectious Conditions and Disease Outbreaks appears in the same volume of the Morbidity Mortality Weekly Report (MMWR) as the annual Summary of Notifiable Infectious Diseases (2).